If you have been reading about copper tripeptide-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) tripeptide complex | Contains glycyl-histidyl-lysine ligand |
| Peptide sequence | Gly-His-Lys | N-terminal glycine, C-terminal lysine |
| Molecular formula | C14H22CuN6O4 | Commonly cited for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility | Water-soluble | Also dissolves in some polar solvents |
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
It has also been reported as a folk remedy for diabetes: since inulin is not assimilated in the intestine, it does not cause a glycemic spike as potatoes would. Temperature variances have been shown to affect the amount of inulin the Jerusalem artichoke can produce. It makes less inulin in a colder region than when it is in a warmer region.
The newer drugs have a better bioavailability as they are not charged and have a non-ionic interaction to the S1 pocket. Rivaroxaban During the SAR development of rivaroxaban, researchers realized that adding a 5-chlorothiophene-2-carboxamide group to the oxazolidonine core could increase the potency by 200 fold, which had previously been too weak for medical use. In addition to this discovery, a clear preference for the (S)-configuration was confirmed. This compound had a promising pharmacokinetical profile and did not contain a highly basic amidine group, but that had previously been considered important for the interaction with the S1 pocket. These findings lead to extensive SAR (structure-activity relationship) researches. During the SAR testing, R1 was defined as the most important group for potency. Pyrrolidinone was the first R1 functional group to significantly increase the potency but further researches revealed even higher potency with a morpholinone group instead. Groups R2 and R3 had hydrogen or fluorine attached and it was quickly assessed that having hydrogen resulted in highest potency. Groups R2 and R3 were then substituted for various groups, which were all less potent than the hydrogen, so hydrogen was the final result. As the chlorothiophene moiety had an inadequate water solubility, substituting it with another group was attempted but was unsuccessful. The chlorothiophene moiety binds to Tyr-228 at the bottom of the S1 pocket, making it a key factor regarding binding to FXa. Rivaroxaban has both high affinity and good bioavailability.
== Versus point of zero charge == The terms isoelectric point (IEP) and point of zero charge (PZC) are often used interchangeably, although under certain circumstances, it may be productive to make the distinction. In systems in which H+/OH− are the interface potential-determining ions, the point of zero charge is given in terms of pH. The pH at which the surface exhibits a neutral net electrical charge is the point of zero charge at the surface. Electrokinetic phenomena generally measure zeta potential, and a zero zeta potential is interpreted as the point of zero net charge at the shear plane. This is termed the isoelectric point. Thus, the isoelectric point is the value of pH at which the colloidal particle remains stationary in an electrical field. The isoelectric point is expected to be somewhat different from the point of zero charge at the particle surface, but this difference is often ignored in practice for so-called pristine surfaces, i.e., surfaces with no specifically adsorbed positive or negative charges. In this context, specific adsorption is understood as adsorption occurring in a Stern layer or chemisorption. Thus, point of zero charge at the surface is taken as equal to isoelectric point in the absence of specific adsorption on that surface. According to Jolivet, in the absence of positive or negative charges, the surface is best described by the point of zero charge. If positive and negative charges are both present in equal amounts, then this is the isoelectric point.
=== Environmental issues === On January 23, 2019, Pritzker committed Illinois to the United States Climate Alliance, which aimed to reduce the state's greenhouse gas emissions by over 26% by 2025. In 2017, it was revealed that both Pritzker and his 2018 gubernatorial primary opponent Christopher G. Kennedy held stock in ExxonMobil, Chevron Corporation, Occidental Petroleum, and ConocoPhillips. In 2024, Pritzker signed the SAFE CCS Act, making Illinois the second state after California to halt approval of carbon dioxide pipelines.
Sources: en.wikipedia.org
Inputs include clinical tests (cold ethyl chloride, EPT, hot-gutta percha, palpation), radiographic analysis (peri-apical and/or cone-beam computed tomography) and others. Thermal tests are subjective, and are therefore performed the compromised tooth and the adjacent and contralateral teeth, allowing the patient to compare them. Normal healthy teeth are used as a baseline for diagnoses. Key characteristics of symptomatic irreversible pulpitis include:
Graham Stuart, MP for Beverley and Holderness, resigns from his ministerial post of Energy Minister with the UK government to spend more time focusing on local issues. He is replaced by Justin Tomlinson. Bambos Charalambous, MP for Enfield Southgate, is readmitted to the Labour Party following a ten month long internal investigation. 13 April – Tim Loughton, MP for East Worthing and Shoreham since 1997, announces he will stand down from parliament at the next election. He becomes the 100th MP to announce they will not seek re-election at the next election. An OpenDemocracy investigation reveals high level Labour politicians met with financial services firms following a £150,000 donation to the party from one of the companies. Simon Geraghty, the former leader of Worcester City Council, announces he will stand down at the May election after 24 years. Leader of Norfolk County Council Kay Mason Billig says that Natural England is blocking the proposed Norwich Northern Distributor Road scheme by protecting a bat colony. Mayor of London Sadiq Khan launches what he describes as a "new climate action plan" for London, which includes a Net Zero Schools target and recommitting to making London Net Zero by 2030. 14 April – Some Conservative MPs and businesspeople are proposing to boycott Downing Street's Eid celebration, scheduled for the following day, because of the UK government's support for Israel. 15 April – Peers living outside London become eligible to claim £100 for accommodation expenses when they attend sittings at the House of Lords.
=== Production during the Manhattan Project === During World War II the U.S. government established the Manhattan Project, for developing an atomic bomb. The three primary research and production sites of the project were the plutonium production facility at what is now the Hanford Site, the uranium enrichment facilities at Oak Ridge, Tennessee, and the weapons research and design lab, now known as Los Alamos National Laboratory, LANL.
== Safety == Hormone therapy for transgender individuals has been shown in medical literature to be generally safe, when supervised by a qualified medical professional. There are potential risks with hormone treatment that will be monitored through screenings and lab tests such as blood count (hemoglobin), kidney and liver function, blood sugar, potassium, and cholesterol. Taking more medication than directed may lead to health problems such as increased risk of cancer, heart attack from thickening of the blood, blood clots, and elevated cholesterol. Hormone therapy has been shown to improve the psychosocial well-being, and lower levels of distress among transgender individuals. Cardiovascular risks vary by hormone regimen, dose, route of administration, age, smoking status, and other individual risk factors. Estrogen therapy is associated with concern about venous thromboembolism, while testosterone therapy may affect cardiovascular risk factors such as blood pressure, lipids, weight, and erythrocytosis. A 2025 Dutch cohort study found that cardiovascular risk patterns differed between transgender women and transgender men receiving gender-affirming hormone therapy: transgender women did not have increased arterial cardiovascular risk compared with general-population men, but had increased venous thromboembolism risk, while transgender men had increased risks of myocardial infarction and ischaemic cerebrovascular accident compared with general-population women.
=== Internet === The NOS is also responsible for the news and sports sites of the Dutch public broadcasters. The editorial staff of the internet pages is also responsible for the teletext pages on NPO 1, NPO 2 and NPO 3.
Sources: en.wikipedia.org
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.
Yes, it is found in human plasma, saliva, and urine. Its concentration in plasma tends to decrease with age. This natural presence is one reason researchers have investigated its role in tissue maintenance.
No, GHK-Cu is not an approved drug in major markets. It is widely used as a cosmetic ingredient, where it is listed under names such as copper tripeptide-1. Any therapeutic claims would require separate regulatory review.
Lyophilized material is normally held at about minus twenty degrees Celsius in a sealed, desiccated vial. Dissolved samples are less durable and are prepared fresh. Repeated freeze-thaw cycles are avoided.